Aims of the study To assess the effectiveness of medicine and immunotherapy on secretory azoospermia. Methods used to conduct the study The husband with azoospermia was 63 years old and his 35-year-old wife presented secondary infertility for 5 years. The male had operation and chemotherapy of stomach cancer five years ago. After operation and chemotherapy,the male made the treatment on immunotherapy until today. In this treatment, andriol and aescuven forte was given. The total treatment were fourteen months. Semen, blood hormone and pregnancy were detected. Results of the study Six months after treatment, sperm appeared in the semen（2018-12-13：sperm concentration 3×106/ml，PR 0%）, ICSI was made while ET was failure. 1 year later, the semen was changed greatly (2019-01-29：sperm concentration 43×106/ml，PR 15%，acrosin 43.1μIU/106), second ICSI was made and TET was failed. In May,2020, third cycle ICSI was made,frozen embryo was transplanted in December and in March the wife was conceived for morn than four months. Conclusions We have discussed and published the medicine treatment of azoospermia in 2017 while it is the first time to find the relationship between the spermatogenesis and immunotherapy. Form this case, it could been concluded that Aescuven Forte with Testosterone Undecanoate is good for the patient with testicle dysfunction whhile the time of medicine treatment is better for more than six months. Immunotherapy might be good for spermatogenesis. FSH is a good for ample in the treatment on azoospermia.

Objective: This study aims to provide an evidence-based assessment of the benefits and harms of four transplantation methods so as to improve the superior pregnancy outcome and reduce the pregnancy rate of multiple embryos in the Mongoloid race. Design: Retrospective analysis Setting: Double Reproductive Centers of Medical University Population or Sample: 24,422 frozen-thawed embryo transfer (FET) cycles recorded from January 2015 to May 2018. Methods：A retrospective cohort study Main Outcome Measures: Biochemical pregnancy, clinical pregnancy, monozygotic twins, miscarriage, maternal complications, live birth. Results: Of the four groups, the biochemical pregnancy rate, the clinical pregnancy rate, and the live birth rate were the lowest in the C-1 group while they were the highest in the B-2 group. However, the B-2 group was accompanied with higher risks of miscarriage, maternal complications, twin births, preterm births and low birth weights. The biochemical pregnancy rates, the clinical pregnancy rates and the live birth rates in the C-2 group and B-1 group were statistically different, with different risks for monozygotic twins, miscarriages. Conclusion: Single blastocyst transplantation seems to be the best choice for all maternal ages to greatly reduce adverse neonatal outcomes. Tweetable abstract: This was a retrospective cohort study using the ART databases from two affiliated hospitals of Peking University. 24,422 frozen-thawed embryo transfer (FET) cycles recorded from January 2015 to May 2018 were selected to generate the research database which also included maternal characteristics.